Last reviewed · How we verify

NCT06851975: BEST

Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

Recruiting now NA Last updated 28 February 2025
What this trial tests

NA trial testing blood sampling in Cancer in 40,000 participants. Currently enrolling.

Timeline
7 January 2020
Primary endpoint
31 December 2099
31 December 2099

Quick facts

Lead sponsorCentre Antoine Lacassagne
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment40,000
Start date7 January 2020
Primary completion31 December 2099
Estimated completion31 December 2099
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Antoine Lacassagne — full company profile →

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Research into biomarkers predictive of survival and response to cancer treatment

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity.
    Cherradi S, Roux S, Bailleux C, Devic C, et al · · 2026 · PMID 41908553 · DOI 10.3389/ftox.2026.1740791

Verify or expand the search:

Other trials of blood sampling

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Centre Antoine Lacassagne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06851975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing